world health day
2022 World Health Day: Why we need climate action at the center of human health?
As we left March and the second anniversary of the pandemic behind, April appears as an ideal opportunity to reflect...
April 4, 2022
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company’s Neuro-Oncology Medical Advisory Board
Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused...
March 21, 2022
Dr. Gerard Blobe, MD, PhD Joins Vivacitas Oncology’s Solid Tumor Medical Advisory Board
Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly...
March 2, 2022
Priorities for the cancer sector and 3 fronts to be addressed in 2022
So we now smoke less, get screened more, and have acknowledged (ish) that preventive healthcare does make the difference. Yet,...
February 23, 2022
Infusion 51a participates in Champions for a Cure Tournament, an event by the To Cure a Rose foundation
Infusion 51a Sponsors the Champions for a Cure Tournament, an Event by To Cure a Rose Foundation
Pinehurst, North Carolina February 21st, 2022 – Infusion 51a LP (“Infusion 51a” or the “Fund”), an impact investment firm funding...
February 23, 2022
Vivacitas Oncology to Present at the 2022 BIO CEO & Investor Conference
Walnut Creek, CA, USA, February 14th, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, will...
February 14, 2022
world health day

2022 World Health Day: Why we need climate action at the center of human health?

As we left March and the second anniversary of the pandemic behind, April appears as an ideal opportunity to reflect on global health and how our wellbeing is intrinsically linked to our mother earth and the treatment we give it.  This year, World Health Day centers on the interdependence between humans health and environmental health. Our species’ existence evolved from and depends on healthy ecosystems, so why are we handling

Read More »

Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company’s Neuro-Oncology Medical Advisory Board

Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director for Dana-Farber Cancer Institute, Center for Neuro-Oncology as a new member of its top-tier Neuro-Oncology Advisory Board. Dr. Reardon was pleased to state, “I am very excited to be

Read More »

Dr. Gerard Blobe, MD, PhD Joins Vivacitas Oncology’s Solid Tumor Medical Advisory Board

Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Gerard Blobe, MD, PhD has joined its Medical Advisory Board. Tina Runk, EVP of Clinical Operations and Director of the company, commented on Dr.  Blobe’s addition to Vivacitas’ team: “We very much appreciate Dr. Blobe’s expertise in gastrointestinal diseases with a special emphasis in colorectal and pancreatic

Read More »

Priorities for the cancer sector and 3 fronts to be addressed in 2022

So we now smoke less, get screened more, and have acknowledged (ish) that preventive healthcare does make the difference. Yet, and regardless of medical technology and cancer death rate falling by nearly a third in the last three decades, cancer continues to be the world-leading cause of death – around 10 million people still die of it every year. The priorities in the oncologic sector for 2022 aim to turn the

Read More »